The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia

Nephrology Dialysis Transplantation

Volumn 34, Issue 2, 2019, Pages 339-346

  Block, Geoffrey A ^a   Rosenbaum, David P ^b   Yan, Andrew ^b   Greasley, Peter J ^c   Chertow, Glenn M ^d   Wolf, Myles ^e  

^a Denver Nephrology   (United States)

^b Ardelyx Inc   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibroblast growth factor 23; Hyperphosphatemia; Phosphate binder; Sodium hydrogen exchanger isoform 3; Tenapanor

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; TENAPANOR; FIBROBLAST GROWTH FACTOR; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL DISEASE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; TREATMENT DURATION; ADVERSE EVENT; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; HEMODIALYSIS; MIDDLE AGED; PROCEDURES;

DOUBLE-BLIND METHOD; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPHOSPHATEMIA; ISOQUINOLINES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; RENAL DIALYSIS; SULFONAMIDES;

EID: 85061478057     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfy061     Document Type: Article

References (42)

1. Hruska KA, Mathew S, Lund R et al. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008; 74: 148-157
2. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747
3. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
4. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19: 429-435
5. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256
6. David V, Martin A, Isakova T et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2016; 89: 135-146
7. Farrow EG, Yu X, Summers LJ et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108: E1146-E1155
8. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
9. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305: 1119-1127
10. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
11. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
12. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
13. Scialla JJ, Xie H, Rahman M et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014; 25: 349-360
14. Mehta R, Cai X, Lee J et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol 2016; 1: 548-556
15. Xie J, Yoon J, An SW et al. Soluble klotho protects against uremic cardiomy-opathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015; 26: 1150-1160
16. Bacchetta J, Sea JL, Chun RF et al. Fibroblast growth factor 23 inhibits extra-renal synthesis of 1, 25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 2013; 28: 46-55
17. Rossaint J, Oehmichen J, Van Aken H et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126: 962-974
18. Chonchol M, Greene T, Zhang Y et al. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol 2016; 27: 227-237
19. Bansal S, Friedrichs WE, Velagapudi C et al. Spleen contributes significantly to increased circulating levels of fibroblast growth factor 23 in response to lipopolysaccharide-induced inflammation. Nephrol Dial Transplant 2017; 32: 960-968
20. Shalhoub V, Shatzen EM, Ward SC et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122: 2543-2553
21. Kalantar-Zadeh K, Gutekunst L, Mehrotra R et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 519-530
22. Isakova T, Ix JH, Sprague SM et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 2015; 26: 2328-2339
23. Block GA, Rosenbaum DP, Leonsson-Zachrisson M et al. Effect of tenapanor on interdialytic weight gain in patients on hemodialysis. Clin J Am Soc Nephrol 2016; 11: 1597-1605
24. Johansson S, Rosenbaum DP, Knutsson M et al. A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol 2017; 21: 407-416
25. Spencer AG, Labonte ED, Rosenbaum DP et al. Intestinal inhibition of the Naþ/Hþ exchanger 3 prevents cardiorenal damage in rats and inhibits Naþ uptake in humans. Sci Transl Med 2014; 6: 227-236
26. Labonte ED, Carreras CW, Leadbetter MR et al. Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J Am Soc Nephrol 2015; 26: 1138-1149
27. Block GA, Rosenbaum DP, Leonsson-Zachrisson M et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol 2017; 28: 1933-1942
28. Merck Millipore. EZHFGF23-32K Human FGF-23 ELISA Kit. http://www.merckmillipore.com/GB/en/product/Human-FGF-23-ELISA-Kit,MM_ NF-EZHFGF23-32K (7 March 2018, date last accessed)
29. Isakova T, Barchi-Chung A, Enfield G et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013; 8: 1009-1018
30. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291
31. Iguchi A, Kazama JJ, Yamamoto S et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency. Nephron 2015; 131: 161-166
32. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011; 26: 2567-2571
33. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 2011; 117: c74-c82
34. Chue CD, Townend JN, Moody WE et al. Cardiovascular effects of sevelamer in stage 3 CKD. J Am Soc Nephrol 2013; 24: 842-852
35. Moe SM, Chertow GM, Parfrey PS et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015; 132: 27-39
36. Block GA, Bushinsky DA, Cheng S et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 2017; 317: 156-164
37. Francis C, David V. Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens 2016; 25: 325-332
38. Chertow GM, Levin NW, Beck GJ et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363: 2287-2300
39. Moe SM, Zidehsarai MP, Chambers MA et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 257-264
40. Block GA, Rosenbaum DP, Korner P et al. Gastrointestinal tolerability of tenapanor to treat hyperphosphatemia in patients on hemodialysis [Abstract]. J Am Soc Nephrol 2017; 28: 373
41. Smith ER. The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol 2014; 9: 1283-1303
42. Ardelyx. An 8-Week, Multicenter, Randomized, Double-Blind, Parallel Group Study With A 4-Week, Placebo-Controlled, Randomized Withdrawal Period To Evaluate The Efficacy, Safety, And Tolerability Of Tenapanor To Treat Hyperphosphatemia In End-Stage Renal Disease Patients On Hemodialysis (ESRD-HD). ClinicalTrials.gov identifier: NCT02675998. https://clinicaltrials.gov/ct2/show/NCT02675998 (7 March 2018, date last accessed)